AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Adenylosuccinate synthetase isozyme 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P30520

UPID:

PURA2_HUMAN

Alternative names:

Adenylosuccinate synthetase, acidic isozyme; Adenylosuccinate synthetase, liver isozyme; IMP--aspartate ligase 2

Alternative UPACC:

P30520; B1AQM5; Q96EG7

Background:

Adenylosuccinate synthetase isozyme 2, known by alternative names such as Adenylosuccinate synthetase, acidic isozyme, and IMP--aspartate ligase 2, plays a pivotal role in purine nucleotide biosynthesis. It catalyzes the first committed step in the biosynthesis of AMP from IMP, crucial in both the de novo pathway and the salvage pathway.

Therapeutic significance:

Understanding the role of Adenylosuccinate synthetase isozyme 2 could open doors to potential therapeutic strategies. Its critical function in purine nucleotide biosynthesis makes it a key target for exploring novel treatments in metabolic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.